16 completed, 2 unknown, 1 terminated. 19 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 16, Unknown 2, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow Intraocular Melanoma: new trials by email Literature Review of Intraocular Melanoma trials Research Report on Intraocular Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye bevacizumab, temozolomide, polymorphism analysis - Intraocular Melanoma | Phase 2 | Unknown | Institut Curie | 35 | 2009-10-01 | 2013-08-26 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery nab-paclitaxel - Intraocular Melanoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 4 | 2008-08-01 | 2016-02-12 |
| Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma cisplatin, sunitinib malate, tamoxifen citrate - Intraocular Melanoma | Phase 2 | Unknown | San Diego Pacific Oncology & Hematology Associates | 50 | 2007-05-01 | 2014-01-10 |
| Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma cyclophosphamide, lenalidomide, sunitinib malate - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 2 | Terminated | National Institutes of Health Clinical Center (CC) | 12 | 2007-04-01 | 2017-03-27 |
| Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer DNA analysis, immunologic technique, pharmacological study - Brain and Central Nervous System Tumors, Intraocular Melanoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 78 | 2006-01-01 | 2024-04-04 |
| AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma cediranib maleate - Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size | Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2006-01-01 | 2018-08-27 |
| Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma ipilimumab, Tyrosinase/gp100/MART-1 Peptides - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | Bristol-Myers Squibb | 77 | 2004-05-31 | 2022-04-14 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 6 | 2003-10-01 | 2014-05-21 |
| Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma lomustine, temozolomide, thalidomide - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2003-07-01 | 2013-01-18 | |
| Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma IFA, 6MHP, GM-CSF - Intraocular Melanoma, Melanoma (Skin) | Phase 1 / Phase 2 | Completed | University of Virginia | 39 | 2003-07-01 | 2014-11-20 |
| Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma aldesleukin, ipilimumab - Intraocular Melanoma, Melanoma (Skin) | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 2003-02-01 | 2013-06-20 | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Virginia | 7 | 2002-08-01 | 2014-12-19 |
| Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 60 | 2002-02-01 | 2014-05-22 |
| Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma gp100 antigen, incomplete Freund's adjuvant, ipilimumab - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | National Cancer Institute (NCI) | 2002-01-01 | 2013-06-20 | |
| Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma pegylated interferon alfa, temozolomide - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-05-01 | 2013-06-05 | |
| PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma PEG-interferon alfa-2b, thalidomide - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 32 | 2001-01-01 | 2013-04-08 |
| Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma temozolomide, thalidomide - Intraocular Melanoma, Melanoma (Skin) | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 1999-12-01 | 2013-06-19 | |
| Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma pyrazoloacridine - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1999-02-01 | 2012-12-17 | |
| Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12 - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 48 | 1998-11-01 | 2014-05-22 |
Uveal Melanoma (19) · Melanoma (15) · Astrocytoma (1) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Chondrosarcoma (1) · Desmoplastic Small Round Cell Tumor (1) · Ependymoma (1) · Familial ependymoma (1) · Glioblastoma (1) · Glioma (1) · Glioma, Subependymal (1) · Gliosarcoma (1) · Lung Neoplasms (1) · Medulloblastoma (1)
Eye Diseases (19) · Eye Neoplasms (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Neoplasms by Site (19) · Neoplasms, Germ Cell and Embryonal (19) · Neoplasms, Nerve Tissue (19) · Neuroectodermal Tumors (19) · Neuroendocrine Tumors (19) · Nevi and Melanomas (19) · Uveal Diseases (19) · Uveal Neoplasms (19) · Skin Diseases (15) · Skin Neoplasms (15) · Skin and Connective Tissue Diseases (15)
incomplete Freund's adjuvant (5) · Temozolomide (4) · Ipilimumab (3) · Thalidomide (3) · sargramostim (3) · Chemotherapy, Adjuvant (2) · Interleukin-12 Subunit p35 (2) · MART-1 Antigen (2) · Sunitinib (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Aluminum Hydroxide (1) · Amplified Fragment Length Polymorphism Analysis (1) · Bevacizumab (1) · Cisplatin (1)
Memorial Sloan Kettering Cancer Center (4) · National Cancer Institute (NCI) (3) · University of Southern California (3) · University of Virginia (2) · Barbara Ann Karmanos Cancer Institute (1) · Bristol-Myers Squibb (1) · Institut Curie (1) · National Institutes of Health Clinical Center (CC) (1) · Ohio State University Comprehensive Cancer Center (1) · San Diego Pacific Oncology & Hematology Associates (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (17) · Canada (1) · France (1)
Jeffrey S. Weber, MD, PhD (3) · Wen-Jen Hwu, MD, PhD (3) · Craig L. Slingluff, MD (2) · Steven A. Rosenberg, MD, PhD (2) · Edward F. McClay, MD (1) · Elaine McWhirter (1) · Kim Kramer, MD (1) · Sophie Piperno-Neumann, MD (1) · Steven K. Libutti, MD (1) · Thomas E. Olencki, DO (1) · Ulka N. Vaishampayan, MD (1) · William H. Sharfman, MD (1)
PMID 25667295, PMID 12039921, PMID 12826605, PMID 12947072, PMID 16087944, PMID 16283570, PMID 18809608, PMID 21106722, PMID 25126421, PMID 28851380, PMID 32161584
N01CM62201 (1), N01CM62203 (1), P30CA006973 (1), P30CA008748 (1), P30CA014089 (1), P30CA022453 (1), P30CA076292 (1), U01CA063437 (1)